# Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

> **NCT04738292** · PHASE2 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 11 (actual)

## Conditions studied

- ER-positive Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Onapristone
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT04738292
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-05
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-05-15
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** funding
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04738292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04738292, "Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04738292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*